• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Escalated-dose radiotherapy did not increase survival in prostate cancer

byKhang DinhandAndrew Bishara
February 28, 2014
in Oncology, Surgery, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1: Escalated-dose conformal radiotherapy with neoadjuvant androgen deprivation did not increase long-term, overall survival for patients with prostate cancer.

2: The escalated-dose regimen did result in prolonged biochemical progression-free survival, although with increased toxicity. 

Evidence Rating: 1 (Excellent)

Study Rundown: This study randomized men with T1b-T3a,N0,M0 prostate cancer with PSA levels <50ng/mL to neoadjuvant androgen deprivation therapy (ADT) plus either high dose (74 Gray over 37 treatments) or low dose (64 Gy over 32 treatments).  The co-primary end points were overall survival, defined as time from randomization to death due to any cause, and biochemical survival, defined as time from randomization to death attributable to prostate cancer or development of metastatic disease, whichever happened first.  The authors found that at 10 years, overall survival was identically 71% in both groups.  However, biochemical progression-free survival was 55% in the high dose group as compared to 43% in the control group.  This study also showed that high dose radiotherapy delays salvage ADT, a treatment that produces unwanted andropausal side-effects.  However, this advantage must be balanced with a well characterized dose-dependent increase in bowel-related adverse effects.  A limitation of this study was that side effect data was only collected for 5 of the 10 years analyzed, which severely limited the cost-benefit analysis of the escalated-dose regimen.  Furthermore, the applicability of results from this trial is constrained given recent technological advances in radiation therapy.

Click to read the story in the Lancet Oncology

RELATED REPORTS

Medbridge turns any phone into a motion-capture coach for at-home rehab

Structured exercise intervention improves survival in colon cancer patients

Cerebral embolic protection does not decrease stroke incidence in TAVI patients

Relevant reading: Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer

In-Depth [phase 3, open-label, randomized controlled trial]: This study was a phase 3, open-label, randomized controlled trial.  The escalated-dose group consisted of 422 men while the control group had 421.  At ten years follow-up, overall survival was 71% in the high-dose group compared to 71% in the low dose group (hazard ratio 0.99, 95% CI 0.77-1.28, p=0.96).  Biochemical progression-free survival at ten years was 55% for the high dose group compared to 43% for the control-dose group (HR 0.69, 95% CI 0.56-0.84, p=0.0003).  Analyses were done on an intention to treat basis and hazard ratios were estimated with Cox regression.

Other articles by this author: Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas, Afatinib shows increased progression-free survival in non-small-cell lung cancer, Slight increased risk of intussusception linked to rotavirus vaccination

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: oncologyprogression-free survivalprostate cancerPSAradiotherapySurgerytreatmentUrology
Previous Post

Nursing staff cuts associated with increased risk of preventable deaths

Next Post

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients

RelatedReports

Active sexting among teens related to sexual activity
AI Roundup

Medbridge turns any phone into a motion-capture coach for at-home rehab

July 10, 2025
Development of a risk index for colorectal cancer screening
Gastroenterology

Structured exercise intervention improves survival in colon cancer patients

July 9, 2025
Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation
Cardiology

Cerebral embolic protection does not decrease stroke incidence in TAVI patients

July 8, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025
Next Post
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients

Lower target oxygen saturation in extremely preterm infants appears safe

Potential overuse of routine postpartum CBC

Undervaccination becoming more common, associated with increased patient admission rates

Childhood immunizations cost-effective and linked to reduced disease burden

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis
  • 2 Minute Medicine Rewind July 14, 2025
  • New obesity framework may reclassify over half of overweight individuals as people with obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.